Business Wire

CA-LIGHTBITS-LABS

Share
Lightbits Labs Launches LightOS® 2.0 with High Availability

Lightbits Labs , the originator and leader in NVMe™ over TCP (NVMe/TCP) software-defined block storage, today launched LightOS® 2.0, enabling full cloud-native persistent storage integration for Kubernetes with unprecedented scaling and availability via clustering.

With the efficiency and convenience of all-flash arrays and the high performance of direct-attached flash storage, LightOS 2.0 enables independent scaling of compute and storage. This solution maximizes Kubernetes functionality, provides ease of migration and delivers fast recovery times following server failure. LightOS 2.0 provides virtual NVMe volumes, delivering low latency and high performance, while at the same time providing high availability via seamless target-side storage server failover. The result is no interruption in service or forced migration due to a drive or storage node failure.

“Lightbits Labs is the only storage solution in production in the market today that allows data centers to take full advantage of NVMe/TCP,” said Lip-Bu Tan, Lightbits Board Member and Founding Managing Partner of WRVI Capital. “The advancements in LightOS 2.0 will ensure that customers can easily scale their infrastructure, and in-turn their business, without compromising performance, efficiency, or cost.”

LightOS 2.0 leverages a Container Storage Interface (CSI) plugin for Kubernetes to address the growing need for third-party storage support for stateful container storage needs. This has become more important as Kubernetes microservices move from stateless to stateful applications. LightOS 2.0 is ideal for containerized environments like Kubernetes that require large-scale clusters with persistent and durable storage for rapid node migration, workload rebalancing, or recovery from failure without copying data over the network. If any computer node in the network fails, data is moved virtually by pointing it to another container. Taken together, LightOS 2.0 allows for lower TCO via higher capacity utilization as well as increased operational efficiency via decreased downtime and infrastructure flexibility.

“At cloud scale, everything fails. LightOS 2.0 is the industry’s first NVMe/TCP scale-out clustered storage solution – protecting against data loss and avoiding service interruptions at scale in the presence of SSD, server, storage, or network failures,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs . “Now containerized applications can enjoy all of the benefits of disaggregated storage using LightOS CSI plugin for Kubernetes, spinning up persistent storage volumes for containerized workloads just as easily as spinning up another container.”

When installed on commodity servers in large-scale data centers, LightOS 2.0 is automatically optimized for I/O intensive compute clusters, such as Kafka, Cassandra, MySQL, MongoDB, and time series databases. Each storage server in the cluster can support up to 64K namespaces and 16K connections. With LightOS 2.0 providing a highly available and durable storage layer, application teams can focus their efforts on developing new services while LightOS 2.0 takes care of the underlying whole storage platform, guaranteeing the availability of and high-performance access to the data.

“It’s clear that customers want on-demand, high performance, always-available storage no matter where their workloads run. As applications move to the edge, we’re excited about the potential of Lightbits LightOS 2.0 to leverage our rich, interconnected datacenter fabrics, providing local flash-style performance without the operational and reliability issues of server installed drives.” – Zachary Smith, Managing Director for Bare Metal, Equinix

LightOS 2.0 provides the following benefits:

  • Software-defined disaggregated storage for cloud data centers delivering direct-attached NVMe SSD performance and up to a 50% reduction in tail latency
  • Optimized for low-cost QLC flash: Extends write endurance of drives and improves write performance without the need to modify applications
  • Fast container migration via CSI persistent and durable storage
  • Standards-based NVMe/TCP block storage access protocol for application-server-to-storage-server communication
  • LightOS clusters leverage standard NVMe-oF 1.1 multipathing with data protection on the storage target side, providing transparency to the client with fast failover
  • Distributed and durable cluster management with fast failover handling
  • No single point of failure in data and control paths
  • Multiple LightOS clusters can exist in the same cloud data center and clients can use multiple clusters simultaneously
  • Support for Kubernetes v1.13 and v1.15 - v1.18 and later for any volume size, number of volumes or Kubernetes size cluster
  • Rolling upgrades allow for LightOS updates without disruption to storage clients
  • Target-side solution that is easy to deploy at scale, without having to touch the network infrastructure or the clients
  • In cases where Kubernetes is integrated with the OpenStack platform, LightOS 2.0 allows for stateful containers through Kubernetes via CSI, or via a Cinder plugin

“LightOS 2.0 is game changing for the data center. It transforms a rack of x86 servers with NVMe drives into a large high-performance highly redundant storage pool connected to applications servers via NVMe/TCP with Kubernetes integration and high availability. Everything is standard in the solution – TCP protocol on Ethernet, network switches, NICs and drivers – without the need to consider specialized and costly new network infrastructure. Thus LightOS protects current investments and boosts deployments at no risk to deliver new SLA levels for modern application workloads. This is the perfect illustration of the Software-Defined Storage philosophy,” says Philippe Nicolas, Analyst Coldago Research.

To learn more about LightOS 2.0, join our upcoming webinar on June 30th at 10 a.m. PT, “Kubernetes Assimilation: Persistence is Futile .” Josh Goldenhar, VP of Product Marketing, will discuss how you can deploy high performance, low latency block storage in Kubernetes environments and get great performance, increased reliability and lower cost. Register now to save your seat.

Lightbits Labs Resources

About Lightbits Labs™

Lightbits Labs, founded in 2016, is a software-defined storage company that brings hyperscale efficiency and flexibility to everyone. Lightbits’ solution delivers composable, disaggregated NVMe/TCP software-defined storage that performs like local Flash. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that from applications’ perspective is indistinguishable from local SSDs. Lightbits Labs is backed by strategic investors including Dell Technologies Capital, Cisco Investments and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye